Fragile sites are preferential targets for integrations of MLV vectors in gene therapy
- A. C. Bester
- , M. Schwartz
- , M. Schmidt
- , A. Garrigue
- , S. Hacein-Bey-Abina
- , M. Cavazzana-Calvo
- , N. Ben-Porat
- , C. Von Kalle
- , A. Fischer
- , B. Kerem*
*Corresponding author for this work
Research output: Contribution to journal › Article › peer-review
45
Scopus
citations